Side-by-side comparison of AI visibility scores, market position, and capabilities
AI voice automation platform handling healthcare phone calls — benefits verification, prior auth, and referrals — at scale. San Francisco CA; raised $52M+ (a16z, GV);
Infinitus Systems is a healthcare AI company that automates the high-volume, repetitive phone call work that burdens provider administrative teams. Founded in 2019 and headquartered in San Francisco, California, Infinitus has raised more than $52 million from investors including Andreessen Horowitz and GV. The company's AI voice agent, called Maya, conducts real-time phone conversations with insurance payers to verify benefits, check prior authorization status, confirm referrals, and gather other eligibility information on behalf of healthcare providers.\n\nTraditionally, benefits verification and prior authorization follow-up requires large teams of staff members spending hours on hold and navigating complex phone trees. Infinitus replaces this manual process with an AI agent that operates around the clock, completing calls faster than human agents and capturing structured data directly into provider workflows. Customers include health systems, specialty practices, revenue cycle management outsourcers, and digital health companies that need to scale patient access operations without proportionally growing headcount.\n\nThe platform is designed for interoperability, delivering results through APIs and direct integrations with EHR systems, practice management software, and RCM platforms. Infinitus has processed tens of millions of healthcare transactions and continues to expand the scope of calls its AI can handle, with a roadmap that includes scheduling, referral coordination, and patient-facing outreach.
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.